Key Takeaways
- CMS announced final 2027 Medicare Advantage payment policies with a projected net average 2.48% increase — representing more than $13 billion in additional sector payments
- CVS shares surged up to 5.20% on Tuesday, with its Aetna division positioned to benefit directly from the rate adjustment
- The agency will maintain the 2024 risk-adjustment methodology for 2027, implementing stricter guidelines on unlinked chart review diagnoses
- Cantor Fitzgerald maintains an Overweight stance with a $95 target, highlighting Medicare Advantage margin improvement as a critical catalyst
- The company’s first-quarter 2026 earnings are scheduled for May 6, with analysts forecasting $2.23 EPS and $94.86 billion in revenue
CVS Health experienced one of its strongest trading sessions in months on Tuesday, propelled by a Medicare Advantage regulatory announcement that lifted managed-care stocks across the board.
The Centers for Medicare & Medicaid Services released its final 2027 Medicare Advantage and Part D reimbursement framework, indicating a net average rate boost of 2.48% — equating to more than $13 billion in additional industry funding for the 2027 calendar year.
For CVS, this development carries significant weight. The company’s Aetna insurance division maintains substantial Medicare Advantage exposure, complementing its pharmacy benefit management and retail pharmacy segments.
Investors interpreted the rate announcement positively. CVS shares advanced as much as 5.20% during Tuesday’s morning session.
Updated Risk-Adjustment Framework Introduces New Variables
The regulatory update included nuanced details beyond the headline rate increase. CMS indicated it will continue utilizing the 2024 risk-adjustment framework for 2027, while excluding diagnoses derived from unlinked chart reviews in standard risk-score computations.
This represents a more stringent approach that could impact insurers who previously relied heavily on coding-intensive reimbursement tactics. For CVS, operating with a diversified business model, market participants seemed to prioritize the funding boost over the risk-adjustment modifications.
The company’s Stars rating performance has shown notable improvement recently. After bonus-eligible Stars scores plummeted from 85% in 2022 to just 21% in 2023 — a period that significantly pressured Medicare Advantage profitability.
Cantor Fitzgerald, which reaffirmed its Overweight rating with a $95 price objective on Monday, noted that while the Medicare Advantage division still needs progress to achieve 3% margins, the firm estimates 2026 individual Medicare Advantage margins have turned slightly positive.
Shares were trading around $73.28 prior to Tuesday’s rally, a valuation that Cantor and other analysts consider below intrinsic value.
Wall Street Maintains Optimistic Outlook Ahead of Quarterly Report
The analyst community has broadly sustained a favorable view on CVS. The stock holds a consensus Buy rating with an average price objective of $92.79.
Recent analyst actions include Bernstein’s upgrade to Outperform with a $94 target in March, Piper Sandler’s continued Overweight rating despite reducing its target to $99, and Argus Research’s maintained Buy recommendation at $90.
Leerink Partners also maintains an Outperform rating with a $98 price target, influenced partly by the recent FTC consent agreement concerning Caremark and Zinc, which the firm interpreted as reducing regulatory overhang.
On the strategic front, CVS recently disclosed an asset purchase agreement with GenieRx Holdings, designating GenieRx as the stalking horse bidder in Omnicare’s bankruptcy sale proceedings.
The company has also added John E. Gallina, previously CFO at Elevance Health, to its board of directors and audit committee.
Looking ahead: CVS will release Q1 2026 results on May 6. Consensus estimates call for earnings per share of $2.23 and revenue of $94.86 billion.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
